Boardroom Alpha
8-K primary document
MBRX · Current Report (Form 8-K) · Filed June 30, 2026

Moleculin Biotech Inc8-K exhibit

ex_983037_source.htm
ex_983037_source.htm

Exhibit 99.1

 

 

 

slide01.jpg

 

 


slide02.jpg

 


slide03.jpg

 


slide04.jpg

 


slide05.jpg

 


slide06.jpg

 


slide07.jpg

 


slide08.jpg

 


slide09.jpg

 


slide10.jpg

 


slide11.jpg

 


slide12.jpg

 


slide13.jpg

 


slide14.jpg

 


slide15.jpg

 


slide16.jpg

 


slide17.jpg

 


slide18.jpg

 


slide19.jpg

 


slide20.jpg

 


slide21.jpg

 


slide22.jpg

 


slide23.jpg

 


slide24.jpg

 


slide25.jpg

 


slide26.jpg

 


slide27.jpg

 


slide28.jpg

 


slide29.jpg

 


slide30.jpg

 


slide31.jpg

 


slide32.jpg

 


slide33.jpg

 


slide34.jpg

 


slide35.jpg

 


slide36.jpg

 


slide37.jpg

 


slide38.jpg

 


slide39.jpg

 


slide40.jpg

 


slide41.jpg

 


slide42.jpg

 


slide43.jpg

 


slide44.jpg

 


slide45.jpg

 


slide46.jpg

 


slide47.jpg

 


slide48.jpg

 


slide49.jpg

 


slide50.jpg

 


slide51.jpg

 


slide52.jpg

 


slide53.jpg

 


slide54.jpg

 


slide55.jpg

 


slide56.jpg

 


slide57.jpg

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer